Phase 1 Pancreatic Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older
- People with pancreatic cancer (PDAC) that has spread or cannot be surgically removed, and whose cancer has continued to grow after chemotherapy, or who were unable to tolerate or were not eligible for chemotherapy
- People with non-small cell lung cancer (NSCLC) that has spread or cannot be surgically removed, whose cancer has continued to grow after appropriate treatments (chemotherapy, immunotherapy, or targeted therapy depending on their cancer type), or who were unable to tolerate or were not eligible for those treatments
- People with a type of breast cancer called HR+/HER2- (ductal or lobular) that has spread or cannot be surgically removed, and whose cancer has continued to grow after at least 2 previous treatments, or who were unable to tolerate or were not eligible for those treatments
- People with triple-negative breast cancer (TNBC) that has spread or cannot be surgically removed, and whose cancer has continued to grow after at least 2 previous treatments, or who were unable to tolerate or were not eligible for those treatments
- People with colorectal cancer (CRC) that has spread or cannot be surgically removed — this applies to the early dose-testing part of the trial only — whose cancer has continued to grow after chemotherapy and, in certain cases, after immunotherapy as well (confirm with trial site)
- People whose tumours show uptake of a specific imaging agent called 68Ga-NNS309 on a scan
Who may not be able to join:
- People with low blood cell counts, including low white blood cells, low red blood cells (haemoglobin below 9 g/dL), or low platelets
- People with a specific type of irregular heart rhythm reading (a prolonged QTcF interval of 470 milliseconds or more on an ECG)
- People whose kidneys are not filtering well enough (creatinine clearance below 60 mL/min)
- People with urinary tract blockages or urinary incontinence that cannot be managed
- People who have received radiation therapy within 4 weeks before the first dose of the trial treatment
- Other criteria set out in the study protocol may also apply (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 1-888-669-6682
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of patients with dose limiting toxicities of [177Lu]Lu-NNS309; Incidence and severity of adverse events and serious adverse events of [177Lu]Lu-NNS309; Dose modifications for [177Lu]Lu-NNS309; Dose intensity for [177Lu]Lu-NNS309
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.